Nervous System Active Pharmaceutical Ingredients Market Size & Share, by Product (Cytokines, Vaccines, Fusion Proteins, Therapeutic Enzymes); Expression System (Mammalian, Microbial Yeast); Application (Diabetes, CVDs, Oncology, Neurological Disorder) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 4212
  • Published Date: May 01, 2023
  • Report Format: PDF, PPT

Companies Dominating the Nervous System Active Pharmaceutical Ingredients Landscape

top-features-companies
    •  Pfizer, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Boehringer Ingelheim International GmbH
    • Bristol Myers Squibb Company
    • Shenzhen Hepalink Pharmaceutical Co. Ltd.
    • GSK plc
    • F. Hoffmann-La Roche Ltd
    • Cipla Inc.
    • Eli Lilly and Company
    • Novartis AG,
    • Teva Pharmaceutical Industries Ltd.

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Boehringer Ingelheim International GmbH to partner with Carthronix, a biopharmaceutical company to develop therapies based on small molecules to cure diseases associated with elderly people. The research & development are further associated with small molecule therapeutics in canine oncology.
  • F. Hoffmann-La Roche Ltd to acquire acceptance from FDA for its Biologics License Applications. The application is associated with untreated diffuse large B-cell lymphoma.

Author Credits:  Smruti Ranjan, Rajrani Baghel


  • Report ID: 4212
  • Published Date: May 01, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The growing presence of chronic diseases across the globe and the growing geriatric population are the major factors driving the growth of the market.

The market size of the Nervous System Active Pharmaceutical Ingredients Market is anticipated to attain a CAGR of 5% over the forecast period, i.e., 2023-2035.

The major players in the market are Boehringer Ingelheim International GmbH, Bristol Myers Squibb Company, Shenzhen Hepalink Pharmaceutical Co. Ltd., GSK plc, F. Hoffmann-La Roche Ltd, Cipla Inc., Eli Lilly and Company, Novartis AG, Teva Pharmaceutical Industries Ltd.

The CVDs segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying